Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.

Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
Mind Cure’s New Medtech Platform Is A Critical Puzzle-Piece
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
Will MindMed NASDAQ Listing Be The Next Sector-Wide Catalyst?
The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?
Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
How Medtech Is Taking Healthcare Into The 21st Century
What is medtech? It's the wave of the future for healthcare.
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
Mydecine begins the dual listing process to obtain an LSE listing.
The 8 Best Reasons To Invest In Psychedelic Stocks
Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.
Mind Cure Health : Announces Geoff Belair as Chief Technology Officer
Mind Cure brings in an expert in fintech to be its new CTO.
Numinus (CSE:NUMI) or Mydecine (CSE:MYCO)? Two Psychedelics Investing Options
Both Numinus and Mydecine have been rising recently on big volume. Which is the better bet?